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Summary of: Jones KD, Burckhardt CS, Deodhar AA, 
Perrin NA, Hanson GC, Bennett RM (2008) A six-month 
randomized controlled trial of exercise and pyridostigmine 
in the treatment of fibromyalgia. Arthritis & Rheumatism 58: 
612–622. [Prepared by Mark Elkins, CAP Co-ordinator.]
Question: Exercise and the acetylcholine esterase inhibitor, 
pyridostigmine, increase growth hormone secretion. Do 
these interventions, alone or in combination, improve pain, 
tender point count, myalgia scores, and other symptoms 
in patients with fibromyalgia? Design: Randomised, 
controlled, factorial trial with concealed allocation. Setting: 
A university tertiary care centre in the USA. Participants: 
Adults with fibromyalgia according to American College of 
Rheumatology criteria. 165 participants were randomised 
to 4 groups: exercise and pyridostigmine, exercise only, 
pyridostigmine only, or a control group. Interventions: The 
exercise regimen involved three group exercise sessions 
per week for 6 months, consisting of aerobic training for 
30 min, strength training for 10 min, flexibility training 
for 5 min, balance training for 5 min, and relaxation for 
10 min. The non-exercise groups received weekly telephone 
calls to discuss dietary intake and a 2-hour monthly visit, 
intended to control for the effects of staff contact. The 
pyridostigmine regimen was 60 mg, three times daily, for 
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6 months. The non-pyridostigmine groups received placebo 
tablets as a control condition. Outcome measures: The 
primary outcomes were pain measured on a 10 cm visual 
analogue scale (VAS), the number of tender points, and 
the total myalgic score. Secondary outcome measures 
included VAS ratings of fatigue, sleep, stiffness, and 
anxiety; the Beck Depression Index; the Quality of Life 
Scale; and clinical tests of flexibility, strength/endurance, 
and balance. Results: 154 participants completed the study. 
No interaction between the two active interventions was 
observed. At the end of treatment, neither intervention 
significantly affected any of the primary outcomes. Exercise 
significantly improved fatigue, by 1 cm (95% CI 0.3 to 1.7) 
on the VAS; lower body flexibility, by 4 cm (95% CI 1 to 
7) on a seated fingertip-to-toe test; and balance, by 27 sec 
(95% CI 10 to 42) on a single-leg stance test. Pyridostigmine 
significantly improved sleep scores, by 1 cm (95% CI 0.3 to 
1.8) on the VAS; and anxiety scores, by 1.1 cm (95% CI 0.3 
to 2) on the VAS. Conclusion: In people with fibromyalgia, 
exercise improves fatigue, flexibility, and balance, while 
pyridostigmine improves sleep and anxiety. When both 
interventions are used simultaneously, both sets of benefits 
are obtained.
[95% CIs calculated by the CAP Co-ordinator.]
Commentary
Fibromyalgia is characterised by widespread pain, 
fatigue, stiffness, disrupted sleep, depression, physical 
deconditioning, and low pain thresholds at specific anatomic 
sites, which are termed tender points (Wolfe 1990). Exercise 
or injections of growth hormone can improve fibromyalgia 
symptoms (Jones 2006, 2007). As a cheaper alternative to 
injections of growth hormone, the drug pyridostigmine can 
be used to stimulate the body’s growth hormone production. 
This factorial trial sought to determine the benefits of 
exercise and pyridostigmine, alone or in combination, in 
patients with fibromyalgia.
This study is of excellent quality, scoring 9/10 on the PEDro 
scale (Maher 2003), although the points awarded for blinding 
apply only to the comparison of pyridostigmine and its 
placebo. The control condition for the exercise comparison 
would not successfully blind the exercise, but would at least 
control for the attention from the investigators. Also, the 
investigators appropriately lowered the usual significance 
level to 0.01 to account for the large number of outcomes.
Both this study and the Cochrane systematic review of 
exercise for fibromyalgia (Busch 2007) found that the effect 
of exercise on pain was almost statistically significant. If 
this new study is incorporated in the next update of the 
review, the new meta-analysis may show that exercise 
significantly improves pain. Furthermore, the Cochrane 
review found no data on flexibility and strength, so this 
study adds important information about these outcomes. 
However, the 4 cm improvement in seated fingertip-to-toe 
distance is of questionable clinical importance.
Pyridostigmine improved a different set of outcomes: 
sleep and anxiety. These mutually exclusive benefits of 
the two interventions suggest that both should be offered 
to fibromyalgia patients. The lack of an interaction effect 
confirms that the combined benefit is equivalent to the sum 
of the benefits of each treatment alone.
As in many long-term trials, patient compliance was 
disappointing, with ~30% of patients attending less than 
half the allocated exercise sessions. Compliance with 
pyridostigmine was higher, but the estimate may have 
been inflated because it relied on patient reports only. 
Nevertheless, even with this level of compliance, the results 
are generally clinically worthwhile.
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